SIREN : 519022214
BIONEXT is a French company founded 16 years ago, specialized in the sector Ingénierie, études techniques. Based in VENETTE (60280), this company of category PME shows in 2024 a revenue of -111 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -110 846 € | 19 956 € | 284 754 € | 781 440 € | 353 747 € | 295 461 € | 216 373 € | 186 980 € | 113 404 € |
| Net income | -384 054 € | -1 283 495 € | -5 842 122 € | -1 109 878 € | 1 999 280 € | -2 856 063 € | 1 327 483 € | 12 600 € | 66 789 € |
| EBITDA | -741 544 € | -441 683 € | -305 231 € | -113 301 € | 2 593 243 € | 5 559 813 € | 6 225 727 € | -70 034 € | -44 089 € |
| Net margin | 346.5% | -6431.6% | -2051.6% | -142.0% | 565.2% | -966.6% | 613.5% | 6.7% | 58.9% |
In 2024, BIONEXT records a net loss of 384 k€. This deficit will reduce equity on the balance sheet.
-110 846 €
-110 846 €
-741 544 €
-1 472 147 €
-384 054 €
669.0%
The debt ratio (= Financial debt / Equity x 100) stands at -24%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -55%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Cash flow represents 758.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
-23.565%
-55.382%
758.58%
-2.112
In 2024, the debt ratio of BIONEXT (-23.57) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of BIONEXT (-55.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of BIONEXT (-2.11) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 15.03. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
15.03
-13.384
In 2024, the liquidity ratio of BIONEXT (15.03) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of BIONEXT (-13.4x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: -300 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 293 days. Excellent situation: suppliers finance 593 days of the operating cycle (retail model). Overall, WCR represents 59859 days of revenue, i.e. -18.4 M€ to permanently finance. Notable WCR improvement over the period (-76%), freeing up cash.
-18 430 790 €
-300 j
293 j
0 j
59859 j
Compare BIONEXT with other companies in the same sector:
Voir toutes les statistiques du secteur Ingénierie, études techniques
The revenue of BIONEXT in 2024 is -111 k€.
BIONEXT recorded a net loss in 2024.
The headquarters of BIONEXT is located in VENETTE (60280), in the department Oise.
The tax return of BIONEXT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIONEXT operates in the sector Ingénierie, études techniques (NAF code 71.12B). See the 'Sector positioning' section above to compare the company with its competitors.